Worth reading
63In focus
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
203
Millions of yen (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationThird quarter of the fiscal year ending May 20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥5,652 million+16.8%
Operating profit¥546 million+59.1%
Ordinary income¥514 million+44.8%
Net income¥338 million+35.7%
Selling, general and administrative expenses¥1,184 million
Gross Profit Margin
rate_pct30.6
Year-on-year change (points)0.6
Operating profit margin
rate_pct9.7
Year-on-year change (points)2.6
Full-year earnings forecast
Net Sales
¥7,700 million
Operating profit
¥700 million
Ordinary income
¥660 million
Net income for the current fiscal year
¥470 million
Annual Dividend
¥26
Payout ratio
22.2 %
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Pharmaceuticals business sales70.7
Health food business revenue81
Chemicals business net sales74.1
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue is progressing above the earnings forecast, while selling, general and administrative expenses remain at planned levelsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revenue Growth¥244 million
- Improvement in cost ratio¥37 million
- Increase in SG&A expenses¥-77 million
- Increase in gross profit from the pharmaceutical business¥139 million
- Increase in gross profit from the health food business¥35 million
- Increase in gross profit from the chemical products business¥107 million
New initiatives
- Initiatives to begin handling newly imported active pharmaceutical ingredients
- Acquisition and launch of in-house manufacturing projects, including synthesis and purification
- Shortening the lead time to project acquisition by utilizing the development center, and acquiring projects through new technology services
- Acquisition of projects through collaboration with other companies, taking the establishment of PFAS water-quality standards as an opportunity
Segment results
Pharmaceuticals Business
Net Sales
¥2,794 million+20.6%
Operating profit
¥440 million
Year-on-year difference119
Health Foods Business
Net Sales
¥932 million+18.0%
Operating profit
¥27 million
Year-on-year difference22
Chemicals Business
Net Sales
¥1,926 million+11.2%
Operating profit
¥80 million
Year-on-year difference62
Financial targets
Equity ratio
43.4 %
NotesDown 3.2 pts from the previous fiscal year-end
Number of employees
Number of Employees203 People
Reference dateEnd of May 2025
NotesExcludes part-time and temporary employees
Annual Dividend
Annual¥26 per share
Payout ratio
22.2 %
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Third quarter of the fiscal year ending May 2026 |
| Net Sales | ¥5,652 million (YoY +16.8%) |
| Operating profit | ¥546 million (YoY +59.1%) |
| Ordinary income | ¥514 million (YoY +44.8%) |
| Net income | ¥338 million (YoY +35.7%) |
| Gross Profit Margin | rate_pct 30.6 / Year-on-year change (points) 0.6 |
| Operating profit margin | rate_pct 9.7 / Year-on-year change (points) 2.6 |
| Selling, general and administrative expenses | ¥1,184 million |
| Full-year earnings forecast | Net Sales ¥7,700 million / Operating profit ¥700 million / Ordinary income ¥660 million / Net income for the current fiscal year ¥470 million / Annual Dividend ¥26 / Payout ratio 22.2 % |
| Progress against full-year forecast | Pharmaceuticals business sales 70.7 / Health food business revenue 81 / Chemicals business net sales 74.1 |
| Self-assessment against the plan | Revenue is progressing above the earnings forecast, while selling, general and administrative expenses remain at planned levels |
| Segment results | Pharmaceuticals Business Net Sales ¥2,794 million (YoY +20.6%) / Operating profit ¥440 million / Health Foods Business Net Sales ¥932 million (YoY +18.0%) / Operating profit ¥27 million / Chemicals Business Net Sales ¥1,926 million (YoY +11.2%) / Operating profit ¥80 million |
| Breakdown of Factors Affecting the Change | Factors Revenue Growth / Amount ¥244 million, Factors Improvement in cost ratio / Amount ¥37 million, Factors Increase in SG&A expenses / Amount ¥-77 million, Factors Increase in gross profit from the pharmaceutical business / Amount ¥139 million, Factors Increase in gross profit from the health food business / Amount ¥35 million, Factors Increase in gross profit from the chemical products business / Amount ¥107 million |
| Number of employees | Number of Employees 203 People / Reference date End of May 2025 / Notes Excludes part-time and temporary employees |
| Financial targets | Equity ratio 43.4 % |
| Annual Dividend | Annual ¥26 per share / Interim Not disclosed / End of period Not disclosed |
| Payout ratio | 22.2 % |
| New initiatives | Initiatives to begin handling newly imported active pharmaceutical ingredients, Acquisition and launch of in-house manufacturing projects, including synthesis and purification, Shortening the lead time to project acquisition by utilizing the development center, and acquiring projects through new technology services, Acquisition of projects through collaboration with other companies, taking the establishment of PFAS water-quality standards as an opportunity |
Items this document does not state (12)
Results for the three months of the current quarterKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The primary factors were increased revenue in all 3 businesses and an improvement in the cost ratio resulting from higher plant utilization and changes in the product mix. Selling, general and administrative expenses increased mainly due to costs associated with the withdrawal from the health food business, but remained at planned levels. The revisions to the full-year forecasts reflect the projected revenue of the pharmaceuticals and chemicals businesses and the projected costs of withdrawing from the health food business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.